Cingulate Inc. Form 8-K Summary
Business Context and Reporting Period
Cingulate Inc. (CING), a Delaware corporation, filed this Current Report on Form 8-K on July 11, 2023. The company is an emerging growth company developing CTx-1301 (dexmethylphenidate), an investigational once-daily stimulant medication for Attention Deficit/Hyperactivity Disorder (ADHD). The filing primarily addresses the announcement of positive top-line results from a Phase 3 adult efficacy and safety trial.
Key Financial Metrics
This filing is a non-financial event report under Items 7.01 and 8.01. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Clinical Results
The material event reported is the completion of the Phase 3 CTx-1301-022 study (NCT05631626). Key findings include:
- Study Design: Assessed 21 adults (ages 18-55) with ADHD in a laboratory classroom setting following a 5-week dose optimization period.
- Efficacy: Subjects on CTx-1301 showed improvements on the Permanent Product Measure of Performance (PERMP) with an average effect size of 1.79 (range 0.88 to 2.6) compared to placebo.
- Statistical Significance: The overall effect size showed a trend toward significance with a p-value of 0.089, attributed to the modest sample size.
- Comparative Data: The observed effect size exceeds the average of 0.73 found in a meta-analysis of long-acting stimulants in adults.
- Duration: Effect sizes of 1.41 at 30 minutes and 0.98 at 16 hours indicate rapid onset and full-day duration.
- Safety: CTx-1301 was well tolerated. Treatment emergent adverse events (TEAEs) occurred in 9% of CTx-1301 subjects versus 30% of placebo subjects.
- Patient Satisfaction: Outcomes regarding overall satisfaction compared to prior ADHD medications were favorable.
Outlook and Management Commentary
Management highlighted the practical significance of the effect sizes, noting they are large enough to be meaningful in a real-world setting. The company intends to submit full results, including safety data and patient-reported outcomes, for presentation at upcoming medical meetings. The filing notes that the study was designed to obtain estimates of effect size and that significant treatment differences were not initially anticipated due to the sample size.
Investor Verification Checklist
- Verify the full statistical analysis and safety data once presented at upcoming medical meetings.
- Confirm the FDA's regulatory pathway and timeline for a New Drug Application (NDA) based on these Phase 3 results.
- Review the company's cash runway and capital requirements, as this filing does not disclose current liquidity or burn rate.
- Assess the commercial potential of a once-daily stimulant in the current ADHD treatment market.